-
RLA-5331 is an iron activator containing anti-androgen. RLA-5331 is used for metastatic castrated tolerant prostate cancer (mCRPC) research.
-
Xentuzumab is an anti-IGF-1/2 mAb, also targets to INSR-A. Xentuzumab inhibits tumor proliferation and induces apoptosis.
-
ARD-69 is a potent PROTAC androgen receptor degrader and induces degradation of AR protein in AR-positive prostate cancer cell lines.
-
KGP94 is a selective inhibitor of cathepsin L. KGP94 has antitumor activity and improves survival of bone metastases bearing mice.
-
Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with IC50s <5 nM , possessing anticancer activity.
-
Indoximod, an immunometabolic adjuvant, is an orally active IDO pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR.
-
Rucaparib is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3). Rucaparib has the potential for CRPC research.
-
XL092 is a potent inhibitor of the activity of Axl, Mer and C-Met kinase with IC50s of <10 nM, respectively. Anti-tumor Activity.
-
Apitolisib is a potent Class I PI3 kinase and mTORC1/2 inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/β/δ/γ, respectively.
-
Anisomycin is a potent protein synthesis inhibitor which interferes with protein and DNA synthesis. Anisomycin is a JNK activator.
Categories
Diseases
Others
Archives
- February 2023 (1)
- December 2022 (1)
- September 2022 (1)
- August 2022 (2)
- February 2022 (1)
- January 2022 (2)
- December 2021 (1)
- November 2021 (1)
- October 2021 (3)
- July 2021 (3)
- June 2021 (3)
- May 2021 (3)
- April 2021 (2)
- March 2021 (1)
- January 2021 (2)
- December 2020 (1)
- October 2020 (2)
- September 2020 (2)
- July 2020 (2)
- June 2020 (1)
- May 2020 (2)
- April 2020 (3)
- March 2020 (1)
- December 2019 (2)
- November 2019 (1)
- October 2019 (1)
- September 2019 (1)
- August 2019 (1)
- April 2019 (2)